Letter to Editor
Hipec in Ovarian Cancer. Why is it Still the Ugly Duckling of Intraperitoneal Therapy?
Pedro Antonio Cascales Campos*, Jose Gil, Pablo Munoz-Ramon and Pascual Parrilla
Hospital Universitario Virgen de la Arrixaca, Department of Surgery, Murcia, Spain
- Corresponding Author:
- Cascales PAC
Hospital Universitario Virgen de la Arrixaca
Department of Surgery, Ctra. Madrid-Cartagena
s/n, 30120 El Palmar, Murcia, Spain
E-mail: [email protected]
Received: December 21, 2015; Accepted: February 10, 2016; Published: February 12, 2016
Citation: Cascales Campos PA, Gil J, Munoz-Ramon P, Parrilla P (2016) Hipec in Ovarian Cancer. Why is it Still the Ugly Duckling of Intraperitoneal Therapy? J Cancer Sci Ther 08:030. doi:10.4172/1948-5956.1000383
Copyright: © 2016 Cascales Campos PA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
What kind of intraperitoneal therapy would be recommend for our mother, sister, wife or daughter if she was diagnosed with advanced ovarian cancer and if we were in the office of an experienced surgeon able to achieve an optimal resection or, even better, a complete resection of her disease? If one was a surgeon who believed in postoperative systemic chemotherapy, one’s argument would be based on the results of the study GOG 172 (which coincided with a clinical alert from the NCI of the United States in favor of this modality of intraperitoneal treatment after optimal surgery in patients with ovarian cancer)